Search research articles
Contact Us
Filters
Showing results (31-40 of 105) with videos related to
Page
of 11
Sort By:
The American Journal of Gastroenterology
|
April 7, 2025
A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases
Yannick Hoffert, Zhigang Wang, Mathurin Fumery, et al.
British Journal of Clinical Pharmacology
|
July 1, 2021
Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease
Zhigang Wang, Bram Verstockt, João Sabino, et al.
Microorganisms
|
July 2, 2021
Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis
Matthias Gijsen, Erwin Dreesen, Pieter Annaert, et al.
British Journal of Clinical Pharmacology
|
May 17, 2020
Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease
Erwin Dreesen, Sophie Berends, David Laharie, et al.
Inflammatory Bowel Diseases
|
March 9, 2016
Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples
Ann Gils, Thomas Van Stappen, Erwin Dreesen, et al.
Journal of Crohn'S & Colitis
|
January 25, 2022
Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies
Liselotte Fierens, Claire Liefferinckx, Eveline Hoefkens, et al.
Pharmaceutics
|
October 23, 2021
Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis
Ruben Faelens, Zhigang Wang, Thomas Bouillon, et al.
The Journal of Antimicrobial Chemotherapy
|
September 9, 2021
Population pharmacokinetics of cefazolin in maternal and umbilical cord plasma, and simulated exposure in term neonates
Omar Elkayal, Karel Allegaert, Isabel Spriet, et al.
Frontiers in Pharmacology
|
June 10, 2022
Editorial: Therapeutic Drug Monitoring (TDM): A Useful Tool for Pediatric Pharmacology Applied to Routine Clinical Practice
Raffaele Simeoli, Thomas P C Dorlo, Lidwien M Hanff, et al.
British Journal of Clinical Pharmacology
|
January 12, 2019
Optimising infliximab induction dosing for patients with ulcerative colitis
Erwin Dreesen, Ruben Faelens, Gert Van Assche, et al.
Page
of 11
Search research articles
Search
Showing results (31-40 of 105) with videos related to
Sort By:
Page
of 11
The American Journal of Gastroenterology
|
April 7, 2025
A Risk Stratification Tool for Relapse After Intravenous-To-Subcutaneous Switching of Infliximab in Patients With Inflammatory Bowel Diseases
Yannick Hoffert, Zhigang Wang, Mathurin Fumery, et al.
British Journal of Clinical Pharmacology
|
July 1, 2021
Population pharmacokinetic-pharmacodynamic model-based exploration of alternative ustekinumab dosage regimens for patients with Crohn's disease
Zhigang Wang, Bram Verstockt, João Sabino, et al.
Microorganisms
|
July 2, 2021
Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients Are Not Affected by Extracorporeal Membrane Oxygenation: A Matched Cohort Analysis
Matthias Gijsen, Erwin Dreesen, Pieter Annaert, et al.
British Journal of Clinical Pharmacology
|
May 17, 2020
Modelling of the relationship between infliximab exposure, faecal calprotectin and endoscopic remission in patients with Crohn's disease
Erwin Dreesen, Sophie Berends, David Laharie, et al.
Inflammatory Bowel Diseases
|
March 9, 2016
Harmonization of Infliximab and Anti-Infliximab Assays Facilitates the Comparison Between Originators and Biosimilars in Clinical Samples
Ann Gils, Thomas Van Stappen, Erwin Dreesen, et al.
Journal of Crohn'S & Colitis
|
January 25, 2022
Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies
Liselotte Fierens, Claire Liefferinckx, Eveline Hoefkens, et al.
Pharmaceutics
|
October 23, 2021
Model-Informed Precision Dosing during Infliximab Induction Therapy Reduces Variability in Exposure and Endoscopic Improvement between Patients with Ulcerative Colitis
Ruben Faelens, Zhigang Wang, Thomas Bouillon, et al.
The Journal of Antimicrobial Chemotherapy
|
September 9, 2021
Population pharmacokinetics of cefazolin in maternal and umbilical cord plasma, and simulated exposure in term neonates
Omar Elkayal, Karel Allegaert, Isabel Spriet, et al.
Frontiers in Pharmacology
|
June 10, 2022
Editorial: Therapeutic Drug Monitoring (TDM): A Useful Tool for Pediatric Pharmacology Applied to Routine Clinical Practice
Raffaele Simeoli, Thomas P C Dorlo, Lidwien M Hanff, et al.
British Journal of Clinical Pharmacology
|
January 12, 2019
Optimising infliximab induction dosing for patients with ulcerative colitis
Erwin Dreesen, Ruben Faelens, Gert Van Assche, et al.
Page
of 11